Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.